Sunitinib

Generic Name
Sunitinib
Brand Names
Sutent, Sunitinib Accord
Drug Type
Small Molecule
Chemical Formula
C22H27FN4O2
CAS Number
557795-19-4
Unique Ingredient Identifier
V99T50803M
Background

Sunitinib is a small-molecule multi-targeted receptor tyrosine kinase (RTK) inhibitor. On January 26, 2006, the agent was formally approved by the US FDA for the indications of treating renal cell carcinoma (RCC) and imatinib-resistant gastrointestinal stromal tumor (GIST). For these purposes, sunitinib is generally available as an orally administered formul...

Indication

Sunitinib is indicated for the following conditions:

Associated Conditions
Gastrointestinal Stromal Tumor (GIST), Renal Cell Carcinoma (RCC), Renal Cell Carcinoma Recurrent, Unresectable, locally advanced Progressive Neuroendocrine Tumors of pancreatic origin, Unresectable, metastatic Progressive Neuroendocrine Tumors of pancreatic origin
Associated Therapies
-
Clinical Trials
Related News

Study in Which Therapy is Either Switched to Nivolumab After 3 Months of Treatment or Therapy is Continued With a Tyrosine Kinase Inhibitor in Patients With Metastatic Renal Cell Carcinoma (RCC) and Disease Control

First Posted Date
2016-11-09
Last Posted Date
2021-09-08
Lead Sponsor
AIO-Studien-gGmbH
Target Recruit Count
49
Registration Number
NCT02959554
Locations
🇩🇪

Universitätsklinikum Essen (AöR) - Klinik und Poliklinik für Urologie / Kinderurologie und Uroonkologie, Essen, Germany

🇦🇹

Medizinische Universität Wien - Universitätsklinik für Innere Medizin I, Klinische Abteilung für Onkologie, Wien, Austria

Combining Sunitinib, Temozolomide and Radiation to Treat Patients Diagnosed With Glioblastoma

First Posted Date
2016-10-10
Last Posted Date
2016-10-10
Lead Sponsor
Bassam Abdulkarim
Target Recruit Count
45
Registration Number
NCT02928575
Locations
🇨🇦

Tom Baker Cancer Center and University of Calgary, Calgary, Alberta, Canada

🇨🇦

McGill University Health Centre, Montreal, Quebec, Canada

The Drug Rediscovery Protocol (DRUP Trial)

First Posted Date
2016-10-05
Last Posted Date
2024-01-24
Lead Sponsor
The Netherlands Cancer Institute
Target Recruit Count
1550
Registration Number
NCT02925234
Locations
🇳🇱

Meander medisch centrum, Amersfoort, Netherlands

🇳🇱

Netherlands Cancer Institute, Amsterdam, Netherlands

🇳🇱

Amsterdam UMC, locatie AMC, Amsterdam, Netherlands

and more 33 locations

Combined Alternating Sunitinib and Bevacizumab (Avastin®) in Advanced Renal Cell Carcinoma (CASA)

First Posted Date
2016-09-29
Last Posted Date
2018-08-10
Lead Sponsor
King Faisal Specialist Hospital & Research Center
Target Recruit Count
77
Registration Number
NCT02919371
Locations
🇸🇦

Oncology Centre, King Faisal Specialist Hospital and Research Centre, Riyadh, Saudi Arabia

Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Axitinib Versus Sunitinib Monotherapy in Participants With Renal Cell Carcinoma (MK-3475-426/KEYNOTE-426)

Phase 3
Active, not recruiting
Conditions
Renal Cell Carcinoma
Interventions
Biological: Pembrolizumab
Drug: Sunitinib
Drug: Axitinib
First Posted Date
2016-08-02
Last Posted Date
2024-11-18
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
861
Registration Number
NCT02853331

Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma

First Posted Date
2016-07-28
Last Posted Date
2016-07-28
Lead Sponsor
Rennes University Hospital
Target Recruit Count
45
Registration Number
NCT02848768
Locations
🇫🇷

CHU de Rennes, Rennes, France

Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma

First Posted Date
2016-06-23
Last Posted Date
2024-11-01
Lead Sponsor
Eisai Inc.
Target Recruit Count
1069
Registration Number
NCT02811861
Locations
🇮🇱

Chaim Sheba Medical Center, Ramat-Gan, Israel

🇯🇵

Facility #2, Tokyo, Japan

🇺🇸

Mount Sinai Medical Center, Miami Beach, Florida, United States

and more 159 locations

Personalized Kinase Inhibitor Therapy Combined With Chemotherapy in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia

First Posted Date
2016-05-20
Last Posted Date
2020-05-26
Lead Sponsor
OHSU Knight Cancer Institute
Target Recruit Count
7
Registration Number
NCT02779283
Locations
🇺🇸

OHSU Knight Cancer Institute, Portland, Oregon, United States

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

First Posted Date
2016-05-04
Last Posted Date
2024-11-13
Lead Sponsor
National Cancer Institute (NCI)
Target Recruit Count
152
Registration Number
NCT02761057
Locations
🇺🇸

Pali Momi Medical Center, 'Aiea, Hawaii, United States

🇺🇸

Queen's Cancer Center - Pearlridge, 'Aiea, Hawaii, United States

🇺🇸

Illinois CancerCare-Peru, Peru, Illinois, United States

and more 593 locations

Efficacy of Rechallenge With Sunitinib in Metastatic Pancreatic Neuroendocrine Tumor Previously Failed to Sunitinib

Phase 2
Completed
Conditions
Pancreatic Neuroendocrine Tumour Metastatic
Interventions
Drug: Sunitinib
First Posted Date
2016-03-21
Last Posted Date
2020-03-04
Lead Sponsor
Grupo Espanol de Tumores Neuroendocrinos
Target Recruit Count
11
Registration Number
NCT02713763
Locations
🇪🇸

Hospital Universitario Valle de Hebrón, Barcelona, Spain

🇪🇸

Instituto Valenciano de Oncología, Valencia, Spain

🇪🇸

Complejo Hospitalario Regional Virgen Del Rocío, Sevilla, Spain

and more 6 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy